← Back to Search

Other

Intermittent Fasting for Crohn's Disease

N/A
Waitlist Available
Led By Sidhartha R Sinha, MD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Mild to moderate Crohn's disease (CDAI score 151-450)
Between the ages of 18-70 (inclusive)
Must not have
Individuals with history of severe cardiac disease (particularly uncompensated congestive heart failure NYHA grade 2 or more or LVEF < 40%)
Women who are pregnant, nursing or expect to be pregnant
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at baseline versus within 6 days after 3rd cycle of ircd. 1 cycle of ircd lasts 5 days and is administered once a month, followed by regular diet for the rest of the month.
Awards & highlights

Summary

This trial is investigating whether an Intermittent Calorie Reduced Diet that mimics fasting could help treat Crohn's disease by reducing inflammation.

Who is the study for?
Adults aged 18-70 with mild to moderate Crohn's disease can join this trial. It's not for those allergic to nuts, severely weakened by illness or medical procedures, with severe heart issues, pregnant/nursing women, or anyone on a calorie-restricted diet. People who've had certain gastrointestinal surgeries or have serious conditions like diabetes at risk of hypoglycemia are also excluded.
What is being tested?
The study tests an Intermittent Reduced Calorie Diet (IRCD) that mimics fasting and is safe according to the FDA. The goal is to see if IRCD reduces inflammation and improves life quality in Crohn's disease patients over five-day periods.
What are the potential side effects?
Potential side effects may include nutritional deficiencies due to reduced calorie intake and possible reactions in individuals sensitive to specific dietary components within the IRCD meal plan.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My Crohn's disease is in the mild to moderate stage.
Select...
I am between 18 and 70 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have severe heart disease, such as bad heart failure or a weak heart pump.
Select...
I am not pregnant, nursing, or planning to become pregnant.
Select...
I have diabetes and am on medication that could lower my blood sugar too much.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~assessed within 6 days after 3rd cycle of ircd. 1 cycle of ircd lasts 5 days and is administered once a month, followed by regular diet for the rest of the month.
This trial's timeline: 3 weeks for screening, Varies for treatment, and assessed within 6 days after 3rd cycle of ircd. 1 cycle of ircd lasts 5 days and is administered once a month, followed by regular diet for the rest of the month. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Change in C-reactive protein (CRP) at baseline versus after 3rd cycle of IRCD (or control at corresponding time point) in both IRCD and control group.
Change in Erythrocyte Sedimentation Rate (ESR) at baseline versus after 3rd cycle of IRCD (or control at corresponding time point) in both IRCD and control group.
Change in fecal calprotectin at baseline versus after 3rd cycle of IRCD (or control at corresponding time point) in both IRCD and control group.
+4 more
Other study objectives
Changes in clinical markers of disease activity
Changes in cytokines/chemokines and immune cell profiles
Changes in gut metabolites (including short-chain fatty acid and bile acid profiles) and microbiome profiles (using 16S rRNA/shotgun metagenomics)
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Intervention ArmExperimental Treatment1 Intervention
Three cycles of a 5-day Intermittent Reduced Calorie Diet
Group II: Control ArmActive Control1 Intervention
Regular Diet

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,448 Previous Clinical Trials
17,492,308 Total Patients Enrolled
Sidhartha R Sinha, MDPrincipal InvestigatorStanford University
2 Previous Clinical Trials
95 Total Patients Enrolled

Media Library

Intermittent Reduced Calorie Diet (IRCD) (Other) Clinical Trial Eligibility Overview. Trial Name: NCT04147585 — N/A
Crohn's Disease Research Study Groups: Intervention Arm, Control Arm
Crohn's Disease Clinical Trial 2023: Intermittent Reduced Calorie Diet (IRCD) Highlights & Side Effects. Trial Name: NCT04147585 — N/A
Intermittent Reduced Calorie Diet (IRCD) (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04147585 — N/A
~15 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top